How much will Aphria owe in August

Aphria Inc is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 6th of August 2020. The stock is in a buyout trend. Aphria Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to increase significantly based on the last few years of reporting. The past year's Earnings Before Interest Taxes and Depreciation Amortization EBITDA were at 8.39 Million. The current year Working Capital is expected to grow to about 796.9 M, whereas Average Assets are forecasted to decline to about 1.9 B. As many investors are getting excited about healthcare space, it is fair to go over Aphria Inc as an investment option. We will evaluate why we are still optimistic in anticipation of a recovery.
Published over a year ago
View all stories for Aphria | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Vlad Skutelnik

This firm currently holds 42.06 M in liabilities with Debt to Equity (D/E) ratio of 0.26, which may suggest the entity is not taking enough advantage from borrowing. The company currently holds 42.06 M in liabilities with Debt to Equity (D/E) ratio of 0.26, which may suggest the stock is not taking enough advantage from borrowing. Aphria Inc has a current ratio of 5.09, suggesting that it is liquid enough and is able to pay its financial obligations when due.

How important is Aphria's Liquidity

Aphria financial leverage refers to using borrowed capital as a funding source to finance Aphria Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Aphria financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Aphria's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Aphria's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Aphria's total debt and its cash.

What is the case for Aphria Investors

The latest price spikes of Aphria Inc could raise concerns from investors as the firm closed today at a share price of 5.08 on 7,732,700 in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in August. The stock standard deviation of daily returns for 30 days investing horizon is currently 5.55. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Aphria partners.

Asset Breakdown

1.6 B
Assets Non Current
992.8 M
Goodwill
968.8 M
Current Assets
Total Assets2.26 Billion
Current Assets968.84 Million
Assets Non Current1.57 Billion
Goodwill992.84 Million
Tax Assets2.97 Million

Will price continue to build-up in August 2020?

Aphria current coefficient of variation builds up over 856.01. Aphria Inc exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Aphria Inc individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Aphria future systematic risk.

The Bottom Line

Whereas some other firms within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Aphria may offer a potential longer-term growth to investors. While some investors may not share our view we believe it may be a good time to quit Aphria as the risk-reward trade off is not appealing enough to hold a position. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aphria.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Aphria Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com